A Spatially Resolved Dark- versus Light-Zone Microenvironment Signature Subdivides Germinal Center-Related Aggressive B Cell Lymphomas.
Cancer
Cancer Systems Biology
Transcriptomics
Journal
iScience
ISSN: 2589-0042
Titre abrégé: iScience
Pays: United States
ID NLM: 101724038
Informations de publication
Date de publication:
23 Oct 2020
23 Oct 2020
Historique:
received:
22
05
2020
revised:
23
07
2020
accepted:
10
09
2020
entrez:
21
10
2020
pubmed:
22
10
2020
medline:
22
10
2020
Statut:
epublish
Résumé
We applied digital spatial profiling for 87 immune and stromal genes to lymph node germinal center (GC) dark- and light-zone (DZ/LZ) regions of interest to obtain a differential signature of these two distinct microenvironments. The spatially resolved 53-genes signature, comprising key genes of the DZ mutational machinery and LZ immune and mesenchymal milieu, was applied to the transcriptomes of 543 GC-related diffuse large B cell lymphomas and double-hit (DH) lymphomas. According to the DZ/LZ signature, the GC-related lymphomas were sub-classified into two clusters. The subgroups differed in the distribution of DH cases and survival, with most DH displaying a distinct DZ-like profile. The clustering analysis was also performed using a 25-genes signature composed of genes positively enriched in the non-B, stromal sub-compartments, for the first time achieving DZ/LZ discrimination based on stromal/immune features. The report offers new insight into the GC microenvironment, hinting at a DZ microenvironment of origin in DH lymphomas.
Identifiants
pubmed: 33083730
doi: 10.1016/j.isci.2020.101562
pii: S2589-0042(20)30754-9
pmc: PMC7522121
doi:
Types de publication
Journal Article
Langues
eng
Pagination
101562Informations de copyright
© 2020 The Author(s).
Déclaration de conflit d'intérêts
A.V. works as Scientist for NanoString Technologies Inc. The remaining authors have nothing to disclose.
Références
Nature. 2000 Feb 3;403(6769):503-11
pubmed: 10676951
N Engl J Med. 2018 Apr 12;378(15):1396-1407
pubmed: 29641966
Cancer Cell. 2020 Apr 13;37(4):551-568.e14
pubmed: 32289277
Nat Rev Immunol. 2015 Mar;15(3):172-84
pubmed: 25712152
N Engl J Med. 2008 Nov 27;359(22):2313-23
pubmed: 19038878
J Clin Oncol. 2015 Sep 10;33(26):2848-56
pubmed: 26240231
Nat Biotechnol. 2020 May;38(5):586-599
pubmed: 32393914
Cell Immunol. 1995 Apr 1;161(2):147-57
pubmed: 7535194
J Clin Oncol. 2019 Jan 20;37(3):190-201
pubmed: 30523716
Nat Immunol. 2012 Nov;13(11):1083-91
pubmed: 23001145
Cancer Discov. 2019 Apr;9(4):546-563
pubmed: 30705065
Nat Med. 2018 May;24(5):679-690
pubmed: 29713087
J Clin Oncol. 2019 Jan 20;37(3):202-212
pubmed: 30523719
Blood. 2012 Sep 13;120(11):2240-8
pubmed: 22740445
Blood. 2018 May 24;131(21):2307-2319
pubmed: 29666115
Sci Rep. 2015 Oct 26;5:15722
pubmed: 26500048
Infect Agent Cancer. 2020 May 6;15:28
pubmed: 32391073
Semin Hematol. 2015 Apr;52(2):67-76
pubmed: 25805586